4Tolley DA,Parmar MK,Grigor KM,et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder eancer:a further report with 7 years of follow up [J]. J Urol, 1996, 155(4): 1233-1238.
5Sylvester RJ,van der Meijden AP,OosterLinck W,et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials [J]. Eur UroL,2006,49( 3 ): 466-477.
7Hara I, Miyake H,Takechi Y, et al. Clinieal outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder [J]. Int J Urol,2003,10( 1 ): 19-24.
8Sylvester RJ, Oosterlinek W,van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with Ta T1 bladder eaneer:a meta-analysis of published results of randomized clinical trials [J].J Urol, 2004, 171 (6 Pt 1):2186-2190.
9van Rhijn B W, Burger M, Lotan Y, et al. Recurrenceand progression of disease in non-muscle-invasive blad der cancer: from epidemiology to treatment strategy [J]- Eur Urol, 2009,56:430-442.
10Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. Eur Urol, 2011, 59:997-1008.
